Royal Bank of Canada Sells 16,517 Shares of DaVita Inc. $DVA

Royal Bank of Canada trimmed its holdings in shares of DaVita Inc. (NYSE:DVA) by 6.4% in the first quarter, HoldingsChannel.com reports. The fund owned 242,615 shares of the company’s stock after selling 16,517 shares during the period. Royal Bank of Canada’s holdings in DaVita were worth $37,285,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of DVA. Root Financial Partners LLC grew its stake in DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after purchasing an additional 105 shares during the period. Caitlin John LLC purchased a new position in shares of DaVita in the 4th quarter worth about $34,000. Canada Pension Plan Investment Board bought a new position in DaVita during the second quarter valued at about $43,000. Sankala Group LLC purchased a new stake in DaVita during the fourth quarter worth about $39,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of DaVita during the 3rd quarter worth approximately $46,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.90% of the stock is currently owned by company insiders.

DaVita Trading Down 2.8%

NYSE:DVA opened at $233.43 on Tuesday. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $247.49. The company has a 50-day moving average price of $218.46 and a 200-day moving average price of $174.48. The stock has a market cap of $14.99 billion, a price-to-earnings ratio of 21.65, a P/E/G ratio of 0.79 and a beta of 0.88.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.00 EPS. Equities analysts forecast that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on DVA shares. Barclays lifted their price objective on DaVita from $194.00 to $218.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 8th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Truist Financial lifted their target price on shares of DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a research report on Tuesday, July 14th. TD Cowen lifted their price target on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research note on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of DaVita in a research note on Monday, June 8th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $216.50.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.